{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T18:30:51Z","timestamp":1761676251553},"reference-count":22,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2014,11,21]],"date-time":"2014-11-21T00:00:00Z","timestamp":1416528000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cytopathology"],"published-print":{"date-parts":[[2015,12]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>When the Sheffield screening laboratory changed the high\u2010risk human papillomavirus (hr<jats:styled-content style=\"fixed-case\">HPV<\/jats:styled-content>) platforms from hybrid capture 2<jats:sup>\u00ae<\/jats:sup> (<jats:styled-content style=\"fixed-case\">HC<\/jats:styled-content>2; Digene Ltd) and to cobas 4800<jats:sup>\u00ae<\/jats:sup> (Roche) an unexpected and substantial increase in the number of cytology\u2010negative\/hr<jats:styled-content style=\"fixed-case\">HPV<\/jats:styled-content>\u2010positive test\u2010of\u2010cure (ToC) samples after large loop excision of the transformation zone (<jats:styled-content style=\"fixed-case\">LLETZ<\/jats:styled-content>) was noted. We explore the potential reasons for these increased rates and discuss the implications this may have on the English <jats:styled-content style=\"fixed-case\">NHS<\/jats:styled-content> cervical screening programme (<jats:styled-content style=\"fixed-case\">CSP<\/jats:styled-content>).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective cohort study with interval analysis between June 2007 and June 2012.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>ToC was performed on 1530 women with <jats:styled-content style=\"fixed-case\">HC<\/jats:styled-content>2 and 396 with cobas 4800: 95.1% and 92.4% of women had negative cytology at ToC in the <jats:styled-content style=\"fixed-case\">HC<\/jats:styled-content>2 and cobas4800 testing period, respectively. Of these 13.9% and 27.8% tested positive for hr<jats:styled-content style=\"fixed-case\">HPV<\/jats:styled-content> in the <jats:styled-content style=\"fixed-case\">HC<\/jats:styled-content>2 and cobas 4800 group, respectively (<jats:italic>P<\/jats:italic>\u00a0=\u00a0&lt;0.0001). No clinically significant increase in the number of cases of cervical intraepithelial neolpasia (<jats:styled-content style=\"fixed-case\">CIN<\/jats:styled-content>) was detected by the cobas4800 test in spite of doubling the number of cytology\u2010negative\/hr<jats:styled-content style=\"fixed-case\">HPV<\/jats:styled-content>\u2010positive ToC samples.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>As far as we are aware, this is the first study reporting potential differences between different <jats:styled-content style=\"fixed-case\">HPV<\/jats:styled-content> platforms currently available in the English programme. The immediate impact of this increase in rates of hr<jats:styled-content style=\"fixed-case\">HPV<\/jats:styled-content> detection with cobas4800 is an increased number of colposcopy referrals to our service. The <jats:styled-content style=\"fixed-case\">NHSCSP<\/jats:styled-content> needs to assess whether this increase is acceptable and, if not, whether specific <jats:styled-content style=\"fixed-case\">HPV<\/jats:styled-content> platforms more suited to screening in a ToC scenario should be recommended.<\/jats:p><\/jats:sec>","DOI":"10.1111\/cyt.12223","type":"journal-article","created":{"date-parts":[[2014,11,21]],"date-time":"2014-11-21T07:29:42Z","timestamp":1416554982000},"page":"381-387","source":"Crossref","is-referenced-by-count":8,"title":["High\u2010risk <scp>HPV<\/scp> platforms and test of cure: should specific <scp>HPV<\/scp> platforms more suited to screening in a \u2018test of cure\u2019 scenario be recommended?"],"prefix":"10.1111","volume":"26","author":[{"given":"A.","family":"Innamaa","sequence":"first","affiliation":[{"name":"Department of Gynaecological Oncology\/Jessop Wing Colposcopy Unit Sheffield Hospitals NHS Trust Sheffield UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Dudding","sequence":"additional","affiliation":[{"name":"Department of Cytology Sheffield Teaching Hospitals NHS Foundation Trust Sheffield UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Ellis","sequence":"additional","affiliation":[{"name":"Department of Cytology Sheffield Teaching Hospitals NHS Foundation Trust Sheffield UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Crossley","sequence":"additional","affiliation":[{"name":"Department of Cytology Sheffield Teaching Hospitals NHS Foundation Trust Sheffield UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. H.","family":"Smith","sequence":"additional","affiliation":[{"name":"East Pennine Cytology Training Centre Department of Histopathology &amp; Cytology Sheffield Hospitals NHS Trust Sheffield UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. A.","family":"Tidy","sequence":"additional","affiliation":[{"name":"Department of Gynaecological Oncology\/Jessop Wing Colposcopy Unit Sheffield Hospitals NHS Trust Sheffield UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. E.","family":"Palmer","sequence":"additional","affiliation":[{"name":"Department of Gynaecological Oncology\/Jessop Wing Colposcopy Unit Sheffield Hospitals NHS Trust Sheffield UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,11,21]]},"reference":[{"key":"e_1_2_6_2_1","unstructured":"MossSM GrayA LegoodR HenstockE.Evaluation of HPV\/LBC cervical screening pilot studies First report to the Department of Health on evaluation of LBC. (December 2002). Available at URLhttp:\/\/www.cancerscreening.nhs.uk\/cervical\/lbc-pilot-evaluation.pdf. Accessed November 2013."},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1300\/J013v43n02_02"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2303.2008.00565.x"},{"key":"e_1_2_6_5_1","unstructured":"MossS KellyR LegoodRet\u00a0al.Evaluation of Sentinel Sites for HPV triage and test of cure. Report to the NHS Cancer Screening Programmes. September 2011. Available at URLhttp:\/\/www.cancerscreening.nhs.uk\/cervical\/sentinelfinalreport.pdf. Accessed November 2013."},{"key":"e_1_2_6_6_1","unstructured":"Digene HC2 High\u2010Risk HPV DNA Test. Qiagen. Available at URLhttp:\/\/www.qiagen.com\/products\/catalog\/assay-technologies\/complete-assay-kits\/hpv-testing\/digene-hc2-high-risk-hpv-dna-test-ce. Accessed November 2013."},{"key":"e_1_2_6_7_1","unstructured":"Cobas\u00ae 4800 System.Roche molecular diagnostics. Available at URLhttp:\/\/molecular.roche.com\/instruments\/Pages\/cobas4800System.aspx. Accessed November 2013."},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.jncimonographs.a003479"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(07)70158-5"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1309\/AJCPZ5JY6FCVNMOT"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1309\/AJCPTGD94EVRSJCG"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/path.1433"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1309\/AJCPTUS5EXAS6DKZ"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2011.09.005"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.06656-11"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2011.07.024"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.05552-11"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0058153"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00181-12"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0059765"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00896-09"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2013-202014"},{"key":"e_1_2_6_23_1","volume-title":"Colposcopy and Programme Management: Guidelines for the NHS Cervical Screening Programme","author":"NHSCSP","year":"2010"}],"container-title":["Cytopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcyt.12223","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cyt.12223","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T13:52:38Z","timestamp":1694440358000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cyt.12223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,21]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["10.1111\/cyt.12223"],"URL":"https:\/\/doi.org\/10.1111\/cyt.12223","archive":["Portico"],"relation":{},"ISSN":["0956-5507","1365-2303"],"issn-type":[{"value":"0956-5507","type":"print"},{"value":"1365-2303","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,21]]}}}